FR2825279B1 - Medicament utile dans le traitement du cancer - Google Patents

Medicament utile dans le traitement du cancer

Info

Publication number
FR2825279B1
FR2825279B1 FR0107285A FR0107285A FR2825279B1 FR 2825279 B1 FR2825279 B1 FR 2825279B1 FR 0107285 A FR0107285 A FR 0107285A FR 0107285 A FR0107285 A FR 0107285A FR 2825279 B1 FR2825279 B1 FR 2825279B1
Authority
FR
France
Prior art keywords
cancer
treatment
useful medicine
medicine
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0107285A
Other languages
English (en)
Other versions
FR2825279A1 (fr
Inventor
Adam Telerman
Robert Amson
Marius Tuijnder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOLECULAR ENGINES LAB
Original Assignee
MOLECULAR ENGINES LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOLECULAR ENGINES LAB filed Critical MOLECULAR ENGINES LAB
Priority to FR0107285A priority Critical patent/FR2825279B1/fr
Priority to US09/885,031 priority patent/US20020193371A1/en
Priority to PCT/FR2002/001861 priority patent/WO2002096400A1/fr
Priority to EP02745475A priority patent/EP1418899A1/fr
Priority to US10/304,964 priority patent/US20030087900A1/en
Publication of FR2825279A1 publication Critical patent/FR2825279A1/fr
Priority to US10/385,509 priority patent/US20040072824A1/en
Application granted granted Critical
Publication of FR2825279B1 publication Critical patent/FR2825279B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0107285A 2001-06-01 2001-06-01 Medicament utile dans le traitement du cancer Expired - Fee Related FR2825279B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0107285A FR2825279B1 (fr) 2001-06-01 2001-06-01 Medicament utile dans le traitement du cancer
US09/885,031 US20020193371A1 (en) 2001-06-01 2001-06-20 Drugs which can be used in the treatment of cancer
PCT/FR2002/001861 WO2002096400A1 (fr) 2001-06-01 2002-06-03 Medicaments utilisables dans le traitement du cancer
EP02745475A EP1418899A1 (fr) 2001-06-01 2002-06-03 Medicaments utilisables dans le traitement du cancer
US10/304,964 US20030087900A1 (en) 2001-06-01 2002-11-27 Drugs which can be used in the treatment of cancer
US10/385,509 US20040072824A1 (en) 2001-06-01 2003-03-12 Methods and compositions for the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0107285A FR2825279B1 (fr) 2001-06-01 2001-06-01 Medicament utile dans le traitement du cancer

Publications (2)

Publication Number Publication Date
FR2825279A1 FR2825279A1 (fr) 2002-12-06
FR2825279B1 true FR2825279B1 (fr) 2005-04-08

Family

ID=8863930

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0107285A Expired - Fee Related FR2825279B1 (fr) 2001-06-01 2001-06-01 Medicament utile dans le traitement du cancer

Country Status (4)

Country Link
US (2) US20020193371A1 (fr)
EP (1) EP1418899A1 (fr)
FR (1) FR2825279B1 (fr)
WO (1) WO2002096400A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097835A2 (fr) * 2002-05-16 2003-11-27 Molecular Engines Laboratories Compositions et procedes destines au traitement du cancer
WO2004080445A1 (fr) * 2003-03-12 2004-09-23 Molecular Engines Laboratories Sa Methodes et compositions pour le traitement du cancer
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
WO2012166579A1 (fr) * 2011-05-31 2012-12-06 Fox Chase Cancer Center Inhibition synergique de voies de signalisation par erbb2/erbb3 dans le traitement du cancer
WO2014018563A2 (fr) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Procédés pour le traitement du cancer
AU2016208673B2 (en) * 2015-01-19 2021-04-01 Belina Pharma Ab Antihistamine for use in treatment of breast cancer
US10766873B2 (en) 2016-01-11 2020-09-08 Centre National De La Recherche Scientifique (Cnrs) Zuclopenthixol hydrochloride derivatives and Ebselen derivatives as ErbB2 inhibitors
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3818977A1 (fr) * 2019-11-06 2021-05-12 Universität Bern Inhibiteurs de cd93 destinés à être utilisés dans le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2426473A1 (fr) * 1978-05-26 1979-12-21 Carraz Gilbert Procede et dispositif de traitement de la leucemie par circulation extra-corporelle du sang
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
US20020193371A1 (en) 2002-12-19
US20030087900A1 (en) 2003-05-08
WO2002096400A1 (fr) 2002-12-05
EP1418899A1 (fr) 2004-05-19
FR2825279A1 (fr) 2002-12-06

Similar Documents

Publication Publication Date Title
CY2016031I1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
NO20044054L (no) Administrering av midler for behandling av betennelse
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60237823D1 (de) Medizinisches behandlungsinstrument
ATE380809T1 (de) Trisubstituiertes aryl- und heteroarylderivate als stoffwechselmodulatoren und die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
NO20055010D0 (no) Preparater inneholdende laktulose for behandling av potavirusinfeksjoner
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
IS7825A (is) Meðferðarfræðileg meðhöndlun
IS6966A (is) Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
FR2825279B1 (fr) Medicament utile dans le traitement du cancer
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
DE60220220D1 (de) Blutbehandlungssystem
NO20020784D0 (no) Medikament for behandling av brudd
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080229